Acrivastine

{{Drugbox

| Verifiedfields = changed | verifiedrevid = 477241254 | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image =Acrivastine.png

| tradename = | Drugs.com = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral

| elimination_half-life = 1.5 hours | excretion = Renal

| CAS_number_Ref =  ^N | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref =  ^Y | ChemSpiderID_Ref =  ^Y | ChemSpiderID = 4447574 | UNII_Ref =  ^Y | UNII = A20F9XAI7W | KEGG_Ref =  ^Y | KEGG = D02760 | ChEMBL_Ref =  ^Y | ChEMBL = 1224 | ChEBI_Ref =  ^N | ChEBI = 83168

| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref =  ^Y | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref =  ^Y | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }}

WikiDoc Resources for Acrivastine
Articles
Most recent articles on Acrivastine Most cited articles on Acrivastine Review articles on Acrivastine Articles on Acrivastine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Acrivastine Images of Acrivastine Photos of Acrivastine Podcasts & MP3s on Acrivastine Videos on Acrivastine
Evidence Based Medicine
Cochrane Collaboration on Acrivastine Bandolier on Acrivastine TRIP on Acrivastine
Clinical Trials
Ongoing Trials on Acrivastine at Clinical Trials.gov Trial results on Acrivastine Clinical Trials on Acrivastine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Acrivastine NICE Guidance on Acrivastine NHS PRODIGY Guidance FDA on Acrivastine CDC on Acrivastine
Books
Books on Acrivastine
News
Acrivastine in the news Be alerted to news on Acrivastine News trends on Acrivastine
Commentary
Blogs on Acrivastine
Definitions
Definitions of Acrivastine
Patient Resources / Community
Patient resources on Acrivastine Discussion groups on Acrivastine Patient Handouts on Acrivastine Directions to Hospitals Treating Acrivastine Risk calculators and risk factors for Acrivastine
Healthcare Provider Resources
Symptoms of Acrivastine Causes & Risk Factors for Acrivastine Diagnostic studies for Acrivastine Treatment of Acrivastine
Continuing Medical Education (CME)
CME Programs on Acrivastine
International
Acrivastine en Espanol Acrivastine en Francais
Business
Acrivastine in the Marketplace Patents on Acrivastine
Experimental / Informatics
List of terms related to Acrivastine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day. Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.